Diagnostics and Laboratory
Technology

INSTRUCTIONS FOR COMPILATION OF A
PRODUCT DOSSIER

Prequalification of Diagnostics

PQDx_018 v1 06.05.2010

Table of Contents
1. Introduction ............................................................................................................ 4
2. Intended Audience .................................................................................................. 5
3. The Product Dossier ................................................................................................ 5
3.1. About the product dossier.……………………………………………………………………….………………….5
3.2. Submission of a product dossier....................................................................................6
4. Dossier Format ........................................................................................................ 7
4.1. Dossier clarity ...............................................................................................................7
4.2. Layout and order...........................................................................................................7
4.3. Language and units of measure.…………………………………………………………………………………..8
5. The Product ............................................................................................................. 8
5.1. Regulatory versions of this product...............................................................................85.2. Product description including variants (configurations) and accessories .......................85.3. Essential principles (EP) checklist ..................................................................................95.4. Risk analysis and control summary..............................................................................10
6. Design and Manufacturing Information...................................................................10
6.1. Product design.............................................................................................................10
6.1.1. Design overview.................................................................................................10
6.1.2. Formulation and composition ............................................................................11
6.1.3. Biological safety .................................................................................................11
6.1.4. Documentation of design changes .....................................................................11
6.2. Manufacturing processes.............................................................................................11
6.2.1. Overview of manufacture...................................................................................11
6.2.2. Sites of manufacture .........................................................................................11
6.2.3. Key suppliers .....................................................................................................12
7. Product Performance Specification, and Associated Validation and Verification
Studies ...................................................................................................................127.1. Analytical studies .........................................................................................................137.1.1. Specimen type ...................................................................................................13
7.1.2. Analytical performance characteristics...............................................................14
7.1.2.1. Accuracy of measurement …………………………………………………………………………… 14
7.1.2.2. Analytical sensitivity........................................................................................15
7.1.2.3. Analytical specificity ........................................................................................15
7.1.2.4. Metrological traceability of calibrators and control material values ................16
7.1.2.5. Measuring range of the assay..........................................................................16
7.1.2.6. Validation of assay cut-off...............................................................................16
7.2. Stability (excluding specimen stability).........................................................................177.2.1. Claimed shelf life................................................................................................17
7.2.2. In use stability ....................................................................................................17
7.2.3. Shipping stability................................................................................................18
7.3. Software verification and validation.............................................................................18
7.4. Clinical evidence (clinical or diagnostic sensitivity and specificity)................................18
7.4.1. Clinical evaluation - Manufacturer .....................................................................18
7.4.2. Clinical evaluation - Independent study..............................................................19
8. Labelling .................................................................................................................20
PQDx_018 v1 06.05.2010
Page 2 of 31

8.1. Labels..........................................................................................................................20
8.2. Instructions for use .....................................................................................................20
9. Commercial History ................................................................................................229.1. Countries of supply .....................................................................................................229.2. Adverse events and field safety corrective actions ......................................................22
10. Regulatory History..................................................................................................23
11. Quality Management System ..................................................................................24
11.1. Quality manual ...........................................................................................................24
11.2. Quality management system documents ....................................................................24
11.3. Quality management system certification...................................................................25
12. Contact Information ...............................................................................................25
13. Reference Documents.............................................................................................25
14. Annex A - Essential Principles (EP) checklist.............................................................27

PQDx_018 v1 06.05.2010
Page 3 of 31

1. Introduction
The World Health Organization (WHO) Prequalification of Diagnostics Programme iscoordinated through the Diagnostics and Laboratory Technology Team (DLT), in thedepartment of Essential Health Technologies (EHT). The aim of the WHO Prequalification of
Diagnostics Programme is to promote and facilitate access to safe, appropriate andaffordable diagnostics of good quality in an equitable manner. Focus is placed on
diagnostics for high burden diseases and their suitability for use in resource-limited settings.
The WHO Prequalification of Diagnostics Programme undertakes a comprehensive
assessment of the submitted products through a standardized procedure which is based on
WHO prequalification requirements. The prequalification of diagnostics process includes
three main components:•••

review of an application form and product dossier;laboratory evaluation of the product; andinspection of the manufacturing site(s).

Another element of the WHO Prequalification of Diagnostics Programme is thestrengthening of the regulatory capacity of WHO Member States to improve pre- and postmarket regulatory oversight of diagnostics.
The findings of the WHO Prequalification of Diagnostics Programme are used to provide
technical information principally to other United Nations (UN) agencies, but also to WHO
Member States and other interested organizations, on particular diagnostic technologies.
The prequalification status of diagnostics, in conjunction with other procurement criteria, isused by UN agencies, WHO Member States and other interested organizations to guide theirprocurement of diagnostics.
Prequalification does not imply any approval by WHO of the diagnostic products andmanufacturing site(s) in question (which is the sole prerogative of national regulatory
authorities). Moreover, prequalification does not constitute any endorsement or warranty
by WHO of the fitness of any product for a particular purpose, including its safety and/or
efficacy in the diagnosis of specific diseases.

PQDx_018 v1 06.05.2010
Page 4 of 31

2. Intended Audience
This document has been prepared to assist manufacturers1 in correctly compiling a productdossier for the purposes of WHO prequalification assessment.
Manufacturers who wish to submit a product dossier for a diagnostic should read thisdocument carefully and compile the product dossier in accordance with the requirements
prescribed below.

3. The Product Dossier
3.1. About the product dossier
There are many terms used internationally to describe a product dossier. These terms
include: standard technical documentation, technical file, summary technical documentation,
product summary file, product master file, and others. For the purposes of prequalification ofdiagnostics, WHO will use the term the product dossier, or simply the dossier.
The manufacturer is expected to prepare, and either hold or provide timely access to,technical documentation that shows how each diagnostic was developed, designed andmanufactured. This technical documentation, typically controlled in the manufacturer's
quality management system (QMS), is often extensive and sections of it may be held in
different locations. The documentation is revised to reflect any changes made during the life
cycle of the diagnostic through normal application of the manufacturer's QMS.
The product dossier is a selection of records and documents from this entire collection ofrecords and documents that a manufacturer holds for a particular product. Manufacturers
compile a product dossier from their existing technical documentation to provide evidence
that the diagnostic conforms to the Essential Principles of Safety and Performance of Medical
Devices2. The information provided may include, for example, abstracts, high levelsummaries, or existing controlled documents, as appropriate, sufficient to communicate key
relevant information and allow a reviewer to understand the subject to assess the validity ofthat information. Furthermore, the dossier should contain an Essential Principles checklist(EP checklist). The content of the submitted product dossier should be traceable by the
manufacturer for future reference.

1

For the purposes of prequalification of diagnostics, the following definition applies: Manufacturer means any
natural or legal person with responsibility for design and/or manufacture of a diagnostic with the intention of
making the diagnostic available for use, under his name; whether or not such a diagnostic is designed and/or
manufactured by that person himself or on his behalf by another person(s).
2

The Global Harmonization Task Force document GHTF/SG1/N41R9:2005 Essential Principles of Safety and
Performance of Medical Devices can be used as guidance document providing requirements of safety andperformance. This document can be accessed through the following website: http://www.ghtf.org/sg1/sg1final.html

PQDx_018 v1 06.05.2010
Page 5 of 31

The EP checklist should be created as part of the manufacturer’s technical documentationand should be controlled by the manufacturer’s QMS. It provides a tabular overview of the
Essential Principles and identifies those that are applicable to the diagnostic, the chosen
method of demonstrating that the device conforms to each relevant Essential Principle andthe reference of the controlled document that is relevant to a specific Essential Principle.
While many controlled documents are referenced in the EP checklist, only some may becontained within the product dossier. The cited references to the controlled documents also
allow easy identification of additional relevant documents and data.
This document describes the elements that a product dossier is expected to contain for the
purposes of the WHO prequalification of diagnostics process. These WHO product dossierrequirements are in-line with those expected by a number of National Regulatory
Authorities. However, as WHO is not a regulator, certain requirements of particular Member
States may not be addressed in the product dossier prepared for the WHO prequalificationof diagnostics process.
WHO reviews the product dossier with the purpose of:•assessing the product and how it performs;•
assessing the product manufacture; and•determining if the manufacturer's quality management system is of an adequate
standard to warrant a WHO prequalification site inspection.
The WHO decision on whether to continue the prequalification assessment to the laboratory
evaluation and manufacturing site inspection stages is based on the review of the dossier.
NOTE: Information that was previously submitted in the Prequalification of Diagnostics APPLICATION FORM: Document PQDx_015 will be considered during the review of the
product dossier. Therefore, manufacturers should ensure that the content of the productdossier is consistent with the information submitted in the application form and that any
changes in the information submitted with the respective application form are promptly
notified to WHO. Furthermore, inadequacies identified at the application form stage andcommunicated by WHO to the manufacturer are expected to be addressed as part of thedossier submission.
3.2. Submission of a product dossier
If an application to the WHO Prequalification of Diagnostics Programme has been acceptedfor prequalification assessment, the manufacturer is notified. Subsequently, a formal letterof agreement is sent by WHO to the manufacturer. This document should be duly signed
and sent back to WHO and a non-refundable prequalification assessment fee of US $12,000.levied before the process can proceed further. Upon completion of these requirements,
WHO formally requests the manufacturer to submit a product dossier. This formal WHO
request includes instructions on where to send the product dossier.

PQDx_018 v1 06.05.2010
Page 6 of 31

NOTE: Manufacturers should not submit a product dossier to WHO unless requested to doso. Dossiers that are submitted without a request from WHO will not be given priority, andthe dossier may be returned to the manufacturer without review.
Manufacturers should ensure that the dossier contains all the information as is prescribed inthis document. The prequalification procedure may be terminated if the dossier does notcontain the prescribed information, or where the information supplied is inadequate tocomplete the prequalification assessment effectively or where the requested information is
not provided by the manufacturer within a specified time period.

4. Dossier Format
4.1. Dossier clarity
A review of WHO processes has identified that poor-quality dossiers take much longer time
for assessment. Therefore, product dossiers should be clear and well-organized to ensurethat the prequalification assessment procedure is efficient for all applicants.
Poorly prepared dossiers may be returned to the applicant without full review. It is
important to keep the needs of the review staff in mind when preparing the product dossier
for submission. This will ensure that the request can be reviewed as quickly as possible.
4.2. Layout and order
Submissions formatted according to the WHO requirements prescribed in this document are
preferred. However, submissions previously prepared for various National Regulatory
Authorities may be accepted if all the information required by WHO is supplied, and if theinformation is fully cross-referenced to the WHO prequalification of diagnostics
requirements using the Product Dossier Checklist document PQDx_049.3
When submitting the product dossier, the following requirements should be fulfilled by the
manufacturer:• WHO requires two hard-copies of the dossier and one electronic-copy (CD or DVD) of theentire dossier.
• The hard-copy dossiers should be provided bound or in a ring-binder. If the dossiercomprises multiple volumes, the volumes should be clearly marked 1 of 2, 2 of 2 etc.
• The hard-copy should be clearly divided into sections, as prescribed in the Product
Dossier Checklist, and the pages of each section should be numbered.
• The hard-copy should include a table of contents.
• The dossier should be submitted using the Product Dossier Checklist (document
PQDx_049) as the first page. All sections of the dossier should be cross-referenced to thisfirst page.

3

This document may be accessed through the following website:
http://www.who.int/diagnostics_laboratory/evaluations/PQDxInfo/en/index.html

PQDx_018 v1 06.05.2010
Page 7 of 31

•

The electronic copy of the dossier should be identical to the hard-copies in regard tocontent.

NOTE: The prequalification assessment process may be terminated if the dossier does notinclude the information prescribed in this document.
4.3. Language and units of measure
For the purposes of prequalification of diagnostics the following requirements apply:• The dossier will be reviewed as an English language document.
• All documents presented in the dossier should be submitted in English (unless otherarrangements have been made with WHO prior to submission of the dossier).
• Any translations of documents should be carried out by a certified translator. Details of
the translator should be provided. The original and the translated document should be
provided.
• Metric units shall be used, except where there are other internationally accepted units ofmeasurement.

5. The Product5.1. Regulatory versions of this productDifferent regulatory requirements apply to different international markets for diagnostics.
Manufacturers who supply a diagnostic into multiple countries often alter some aspects of asingle product to comply with such varying regulatory requirements (for example: varied
information within the instructions for use, different intended purpose statements, different
batch release procedures, or different information on package labels).
If this product has multiple regulatory versions, the manufacturer should provide
information regarding these different regulatory versions. This information should cover all
aspects that are different between these product regulatory versions including (but notlimited to) differences in design, manufacturing, quality control, release for supply, and postmarket practices.
NOTE: If the product has multiple regulatory versions, the information included in the
product dossier should clearly indicate which regulatory version of the product is submitted
for prequalification assessment.
5.2. Product description including variants (configurations) and accessories
The dossier should include the following product descriptive information:
1. The intended use of the diagnostic. This may include:a) what is detectedb) the function of the product (e.g. screening, monitoring, diagnostic or aid to diagnosis,
staging or aid to staging of disease);c) the specific disorder, condition or risk factor of interest that it is intended to detect,define or differentiate;d) whether the product is automated or not;PQDx_018 v1 06.05.2010
Page 8 of 31e) whether the test is qualitative or quantitative.
f) the type of specimen(s) required (e.g. serum, plasma, whole blood, sputum, urine);g) the intended testing population (e.g. neonates, antenatal women).
2. The intended user (laboratory professional and/or at point-of-care);
3. A general description of the principle of the assay method or instrument principles ofoperation.
4. A description of the components of the assay (e.g. reagents, assay controls andcalibrators), and where appropriate, a description of the reactive ingredients of relevant
components (such as antibodies, antigens, nucleic acid primers).
5. A description of the specimen collection and transport materials provided with the
product or descriptions of specifications recommended for use.
6. For instruments of automated assays: a description of the appropriate assay
characteristics or dedicated assays.
7. For automated assays: a description of the appropriate instrumentation characteristics
or dedicated instrumentation.
8. If applicable, a description of any software to be used with the product.
9. If applicable, a description or complete list of the various configurations/variants ofproduct that will be made available.
10. If applicable, a description of the accessories, and other products that are intended to be
used in combination with the diagnostic.
The instructions for use may be used to provide some of this information on the condition
that a cross-reference to the different requirements is supplied in conjunction with the
instructions-for-use.
5.3. Essential principles (EP) checklist
The product dossier should include an EP checklist that identifies:•
the Essential Principles of Safety and Performance;•
whether each Essential Principle applies to the diagnostic and if not, why not;•the method used to demonstrate conformity with each Essential Principle that applies;
and•the reference to the actual technical documentation that offers evidence of conformity
with each method used.
The method used to demonstrate conformity may include one or more of the following:•
conformity with recognized or other standards;•
conformity with a commonly accepted industry test method (reference method);•
conformity with appropriate in-house test methods that have been validated andverified;•comparison to a diagnostic already available on the market.
The EP checklist should include a cross-reference to the location of such evidence bothwithin the full technical documentation held by the manufacturer and within the dossier(when such documentation is specifically required for inclusion in the dossier as outlined inthis instructions).
A sample EP checklist is included in Annex A.
PQDx_018 v1 06.05.2010
Page 9 of 31

5.4. Risk analysis and control summary
A risk analysis should be undertaken to identify and address all known or foreseeable
hazards4 for the product, taking into account such aspects as the user/s of the device, andthe technology involved. The dossier should contain a summary of the risks identified during
the risk analysis process and a description of how these risks have been controlled to an
acceptable level. Furthermore, the risk analysis should be part of the manufacturer's risk
management plan.
Where specific standards or guidelines are recommended by WHO, these should be followed.
The information provided in the dossier should address possible hazards for the diagnostic
such as the risk from false positive or false negative results, indirect risks which may result
from product-associated hazards, such as instability, which could lead to erroneous results,
or from user-related hazards, such as reagents containing infectious agents.
The results of the risk analysis should provide a conclusion with evidence that remaining
risks are acceptable when compared to the benefits.
If the manufacturer holds a certificate issued by a conformity assessment body and related
to risk management of the product under assessment, certified copies should be annexed tothe dossier.

6. Design and Manufacturing Information
This section of the dossier should provide an overview of the design and manufacturing
processes for the product under assessment, including a flow chart of the entire process. If
design and manufacture is carried out at different sites, or by external suppliers, this should
be indicated on the flow chart. The manufacturer should only refer to sites of suppliers of
raw materials involved in critical design and manufacturing activities.
Where Quality Management System certificates, or the equivalent, exist for any sites,
certified copies should be annexed to the dossier.
6.1. Product design
6.1.1. Design overview
The dossier should contain information to allow a reviewer to obtain a general
understanding of the design applied to the product. It should include a description of thecritical ingredients of an assay such as antibodies, antigens, enzymes and nucleic acidprimers, provided or recommended for use with the product.
If design takes place at multiple sites, a controlling site should be identified.

4

Examples of possible hazards and contributing factors associated with diagnostics are given in the ISO
14971:2000(E).
PQDx_018 v1 06.05.2010
Page 10 of 31

6.1.2. Formulation and composition
For each of the ingredients, provide formulation/composition information. For example,
include information such as nucleic acid sequences for primers, ingredient lists for buffers,
amino acid sequence details for recombinant proteins, etc.
Identify the sources of the materials from which the components are constructed.
6.1.3. Biological safety
List all biological components included in the product under assessment. This should include
material of bacterial, viral, parasitic, animal, or human origin, such as plasma, cells, tissues,or their derivatives. The list should include:• the name of the biological component• details of the use of the biological component in the product• description of steps taken for the reduction of transmission or infection risk.
Wherever possible, manufacturers should look to internationally accepted methods for
reducing - and determining residual risk of - transmission or infection risk from biologicalagents. Where specific standards or guidelines are recommended by WHO, these should be
followed.
6.1.4. Documentation of design changes
The dossier should include records of each design change and the reasons for these,
together with any associated validation/verification data. The documentation should include
evidence for believing that the change achieves the desired effect, and that the productcontinues to comply with the Essential Principles of Safety and Performance.
6.2. Manufacturing processes
6.2.1. Overview of manufacture
The dossier should contain information to allow the reviewer to obtain a general
understanding of the manufacturing process. This section is not intended to take the place ofmore detailed information required for a QMS audit or other conformity assessment activity.
The manufacturer should provide details of each major step in the manufacturing process, toclarify the manufacturing steps. Include information on the manufacturing process for allcomponents. The information may take the form of a process flow chart showing, forexample, an overview of production including the technologies used, assembly, any inprocess and final product testing, and packaging of the finished product.
Details of verification, validation and quality-control activities should be provided for all
stages of design and manufacture (including purchased components, in-process products,
and finished products).
6.2.2. Sites of manufacture
A list of all critical manufacturing sites that are involved in the manufacture of this productshould be provided. This should cover all stages of manufacture (including design,
PQDx_018 v1 06.05.2010
Page 11 of 31

warehousing, and quality-control stages of manufacture), but may not need to include thesites of supply of raw materials if they are not considered critical. For each site include:• the name of site;• the physical address of the site;• a description of the component manufacture/stage of the manufacturing process carriedout at the site;• a description of the manufacturing site;• a simple site plan highlighting production areas;• the number of employees at the site;• a description of any other manufacturing that occurs at this site.
NOTE: If a product is successfully prequalified, only product manufactured at the sites thathave been presented in the product dossier will be considered to be prequalified. Anychanges to sites of manufacture should be notified to WHO prior to implementation of thechanges.
6.2.3. Key suppliers
List all key suppliers which supply ingredients/products/services for the manufacture of thisproduct. For each supplier include:• a description of the ingredient/product/service supplied;• the name of the supplier;• the physical address of the supplier's manufacturing facilities;• details of the documented procedures used for the purchasing and verification ofingredients/products/services sourced from these suppliers.
If the manufacturer holds a certificate issued by a conformity assessment body and related
to the quality management system, certified copies should be annexed to the dossier.
NOTE: WHO should be notified of all variations made to a prequalified product. This includes
changes of key suppliers and components/products/services provided by key suppliers.

7. Product Performance Specification, and Associated Validation andVerification Studies
WHO requires the manufacturer to have carried out relevant investigations to support any
performance claims such as analytical and clinical sensitivity and specificity, accuracy,
repeatability, reproducibility, detection limits, and traceability. Investigations should also
have been undertaken to assess the potential effects of interfering factors and claims ofreagent and product stability.
Such performance evaluations may be based upon pre-existing data, scientific literature, or
new studies carried out for the purpose of setting (validating) or verifying performance
claims. Where data does not directly relate to the product, but for example, to similar
products, a rationale explaining the relationship of the product to that used in the study
should accompany such data.
PQDx_018 v1 06.05.2010
Page 12 of 31

The information provided in this section of the dossier will vary in the level of detail asdetermined by clinical risk of the product, its technical complexity, its novelty5, whether it
has been associated with a significant number of adverse events, including use errors, and if
it or a similar product is associated with specific public health concerns.
A summary of outcomes should be provided that contains enough information to allow WHO
to assess the validity of that information. It should include any references to relevantinternational or published standards or guidelines that have been applied in the productionof the data. It should also include a review of relevant published literature regarding the
product or substantially similar products.
Detailed information on each performance claim should be provided and include:•
the complete study protocol•
the method of data analysis•
the complete study report•
the study conclusion.
Actual test result summaries with their acceptance criteria should be provided and not justpass/fail statements.
7.1. Analytical studies
7.1.1. Specimen typeThis section should describe the different specimen types that can be used with the product.
This should include their stability and storage conditions.
Stability includes storage and, where applicable, transport conditions. Storage includes
elements such as duration, temperature limits and freeze/thaw cycles.
This section should include detailed information for each matrix and anticoagulant, whenapplicable, including a description of the measurement procedure for comparison or
determination of measurement accuracy. This includes information such as specimen types
tested, number of samples, sample range (using spiked samples, as appropriate) or target
concentrations tested, calculations and statistical methods, results and conclusions.

5

A product is considered novel if it has any of the following characteristics:
It incorporates novel technology, which many mean that there is no other similar product on the market
for that particular analyte or the procedure involves analytical technology not continuously used inconnection with the given analyte or other parameter on the market.
•
It is an already marketed product that is now being offered for an intended use different from the originalone.
•
It incorporates novel or potentially hazardous materials.
•

PQDx_018 v1 06.05.2010
Page 13 of 31

7.1.2. Analytical performance characteristics
7.1.2.1. Accuracy of measurement
This section should describe both trueness and precision studies 6.
While measurement trueness, affected by systematic error, is normally expressed in termsof bias, and measurement precision, affected by random error, is naturally expressed interms of standard deviation, accuracy is affected by a combination of systematic andrandom effects that contribute as individual components of the total error of measurement.
7.1.2.1.1. Trueness of measurement
This section should provide information on the trueness of the measurement procedure andsummarize the data in sufficient detail to allow assessment of the adequacy of the selectedmeans. Trueness measures apply to both quantitative and qualitative assays only when areference standard or method is available.
7.1.2.1.2. Precision of measurement
This section should describe repeatability and reproducibility studies.
7.1.2.1.2.1. Repeatability:
This section should include repeatability estimates and information about the studies used
to estimate, as appropriate, within-run variability7.
Such studies should include the use of samples that represent the full range of expected
analyte (measurand) concentrations that can be measured by the product, as claimed by the
manufacturer.
For products to be used at point-of-care, where the testing may be undertaken by nonlaboratory staff (for example, clinic nurses), it is necessary to establish these specifications
using firstly professional laboratory personnel to undertake the tests. This will establish the
optimal performance characteristic of the device under controlled laboratory conditions. A
consumer field evaluation should also be conducted to determine the product’s
performance when used by lay users, unassisted, following instructions provided with the
product.

6
The general term "measurement accuracy" is currently used to cover both trueness and precision, whereas
this term was used in the past to cover only the one component now named trueness.
7

If a standard recognized by WHO is used, a declaration/certificate of conformity to the recognized standard
along with a summary of the data and conclusions should be provided.
PQDx_018 v1 06.05.2010
Page 14 of 31

7.1.2.1.2.2. Reproducibility:
This section should include reproducibility estimates and information about the studies used
to estimate, as appropriate, variability between-days, runs, sites, lots, operators andinstruments. Such variability is also known as intermediate precision8.
Such studies should include the use of samples that represent the full range of expected
analyte (measurand) concentrations that can be measured by the product, as claimed by the
manufacturer.
For products to be used at point-of-care, where the testing may be undertaken by nonlaboratory staff (for example, clinic nurses), it is necessary to establish these specifications
using firstly professional laboratory personnel to undertake the tests. This will establish the
optimal performance characteristic of the device under controlled laboratory conditions. A
consumer field evaluation should also be conducted to determine the product’s
performance when used by lay users, unassisted, following instructions provided with the
product.

7.1.2.2. Analytical sensitivity
This section should include detailed information about the study design and results. It should
provide:•a description of specimen type and preparation including matrix, analyte (measurand)
levels, and how levels were established;•
the number of replicates tested at each concentration;•a description of the calculation used to determine assay sensitivity.
For example:
The number of standard deviations above the mean value of the sample without analyte(measurand), commonly referred to as limit of blank (LoB).
•
The lowest concentration distinguishable from zero, based on measurements of samples
containing analyte (measurand), commonly referred to as limit of detection (LoD).
•
Lowest concentration at which precision and/or trueness are within specified criteria,
commonly referred to as limit of quantitation (LoQ).
•

7.1.2.3. Analytical specificity
This section should describe interference and cross reactivity studies to determine theanalytical specificity, defined as the ability of a measurement procedure to detect ormeasure only the analyte (measurand) to be detected, in the presence of othersubstances/agents in the sample.
Provide detailed information on the evaluation of potentially interfering and cross reacting
substances/agents on the assay. Information should be provided on:•
the substance/agent type and concentration tested•
sample type8

See footnote 6.
PQDx_018 v1 06.05.2010
Page 15 of 31

••analyte (measurand) test concentration andresults.

NOTE: Interferents and cross reacting substances/agents, which vary greatly depending on
the assay type and design, could derive from exogenous or endogenous sources such as:•
substances used for patient treatment (e.g. therapeutic drugs, anticoagulants, etc.);•
substances ingested by the patient (e.g. over the counter medications, alcohol, vitamins,
foods, etc.);•
substances added during sample preparation (e.g. preservatives, stabilizers);•
substances encountered in specific specimens types (e.g. haemoglobin, lipids, bilirubin,
proteins)•
analytes of similar structure (e.g. precursors, metabolites) or medical conditions
unrelated to the test condition including specimens negative for the assay but positive
for a condition that may mimic the test condition (e.g. for a hepatitis A assay: test
specimens negative for hepatitis A virus, but positive for hepatitis B virus).
Typically, interference studies involve adding the potential interferent to the sample anddetermining any bias of the test parameter relative to the control sample to which nointerferent has been added.
7.1.2.4. Metrological traceability of calibrators and control material values
Detailed information should be provided about the metrological traceability of values
assigned to calibrators and trueness control materials. Include, for example, methods andacceptance criteria for the metrological traceability to reference materials and/or reference
measurement procedures and a description of value assignment and validation.
NOTE: Precision control materials used when establishing the reproducibility of ameasurement procedure do not require the assessment of metrological traceability to areference material or a reference method.
7.1.2.5. Measuring range of the assay
This section should include detailed information on studies which define the measuring
range (linear and non-linear measuring systems), including the limit of detection, anddescribe information on how these were established. This information should include:•
a description of specimen type, number of samples, number of replicates, andpreparation;•
information on matrix, analyte (measurand) levels and how levels were established;•
if applicable, a description of high dose hook effect and the data supporting the
mitigation (e.g. dilution) steps.
7.1.2.6. Validation of assay cut-off
This section should provide detailed information on analytical data with a description of thestudy design, including methods for determining the assay cut-off, including:•the population(s) studied (demographics / selection / inclusion and exclusion criteria /number of individuals included);•
the method or mode of characterization of specimens; andPQDx_018 v1 06.05.2010
Page 16 of 31•

the statistical methods e.g. Receiver Operator Characteristic (ROC) to generate results
and, if applicable, define gray-zone/equivocal zone.

7.2. Stability (excluding specimen stability)
This section should describe claimed shelf life, in use stability and shipping studies9.
Wherever possible, the manufacturer should look to internationally accepted methods fordetermining stability of diagnostics10. Where specific standards or guidelines for stability
study design and implementation are recommended by WHO, these should be followed.
NOTE: The manufacturer should provide sufficient detail to support stability claims. The
provision of stability data alone is not sufficient. The information described above should be
provided in a clear manner, such that it can be easily reviewed.
7.2.1. Claimed shelf life
This section should provide detailed information on stability testing studies to support theclaimed shelf life. Testing should be performed on at least three different lots manufactured
under conditions that are essentially equivalent to routine production conditions (these lots
do not need to be consecutive lots). Accelerated studies or extrapolated data from real time
data are acceptable for initial shelf life claim but need to be followed up with real timestability studies.
Such detailed information on stability testing studies should include:
the study report (including the protocol, number of lots, acceptance criteria and testing
intervals);•
when accelerated studies have been performed in anticipation of the real time studies,
the method used for accelerated studies;•conclusions and claimed shelf life.
•

NOTE: Shelf life can be derived from the lot with the longest real time stability data as longas accelerated or extrapolated data from all three lots are comparable.
7.2.2. In use stability
This section should provide detailed information on in use stability studies for one lotreflecting actual routine use of the device (real or simulated). This may include open vial
stability and/or for automated instruments, on board stability.
In the case of automated instrumentation, if calibration stability is claimed, supporting data
should be included.
Such detailed information should include:
the study report (including the protocol, acceptance criteria and testing intervals)•

9

Shelf-life, in-use stability and shipping stability information provided under this section should be consistent
with the instructions for use and product labels provided within the product dossier.
10
See reference documents under Section 13.
PQDx_018 v1 06.05.2010
Page 17 of 31•the conclusion and the claimed in use stability.

7.2.3. Shipping stability
This section should provide detailed information on shipping stability studies for one lot toevaluate the tolerance of products to the anticipated shipping conditions.
Shipping studies can be done under real and/or simulated conditions and should include
variable shipping conditions such as extreme temperature (heat and/or cold), humidity, lightand/or pressure.
Such detailed information should include:•
the study report (including the protocol and acceptance criteria)•
the method used for simulated conditions•
the conclusion and the recommended shipping conditions.
7.3. Software verification and validation
The dossier should contain detailed evidence of the validation of the software, as used in thefinished product. This information should typically include the summary results of all
verification, validation and testing performed in-house and, as applicable, in an actual user
environment prior to final release. It should also address all of the different hardware
configurations and, where applicable, operating systems identified in the labelling.
7.4. Clinical evidence (clinical or diagnostic sensitivity and specificity)
Clinical evaluation is the assessment and analysis of data generated from the clinical use of
the product in order to verify the clinical safety and performance of the device. Clinicalevidence is the combined information yielded by the clinical data and its evaluation. It isnecessary for a manufacturer to hold clinical evidence of any clinical claims. This will include
claims for clinical or diagnostic sensitivity and specificity.
7.4.1. Clinical evaluation - Manufacturer
All performance claims should be supported by well-designed performance evaluations
which have been carried out or coordinated by the manufacturer11. Provide information forthese performance evaluations which should include:• A detailed written plan and protocol which explains the intent of the evaluation study
and the way in which the study was performed.
• The date/s on which the study was performed and by which site.
• A written report on the outcome of study. This report should explain how the study
results support the product clinical claims. Any anomalous results, or results that are notwithin predetermined specifications, should be clearly explained or justified.
• Clear identification of the product and product version that is being evaluated.
• Details of the product lots/batches used for the evaluation, including lot number, date of
expiry, and the storage conditions of the product prior to and during the study.

11

The Common Technical Specifications for in vitro diagnostic medical devices (2009/886/EC) of the European
Communities can be considered a guide for establishing clinical specifications. However, the clinical evaluation
should utilize samples obtained form populations equivalent to where this product will be supplied.
PQDx_018 v1 06.05.2010
Page 18 of 31

•
•
•
•

Details of the geographical region and the clinical status of the subjects from which
specimens have been drawn for the clinical evaluation.
Full details of the methods used to define the clinical status of the subjects and tocharacterize the specimens.
Full details of statistical methods, estimations and calculations applied.
Evidence that the outcomes of the performance studies have been reviewed andaccepted for implementation.

NOTE: Actual test results and their acceptance criteria should be provided, and not justpass/fail statements. All data provided should be clearly labeled, and should be clearly linked
to the study report. Furthermore, all abbreviations used in reports and on data records
should be defined and spelt out in full.
7.4.2. Clinical evaluation - Independent study
Details of at least one well-designed independent performance evaluation for the productunder assessment should be included. Only include information from independent
performance evaluations that have been carried out by centres that have the capability of
performing scientifically sound evaluation studies for the product in question.
Scientifically sound performance evaluations should include:
the evaluation study design, study protocol, results, and conclusions;the date/s on which the study was performed;
clear identification of the product and product version that is being evaluated;details of the product lots/batches used for the evaluation, including lot number, date of
expiry, and the storage conditions of the product prior to and during the study;• details of the geographical region and the clinical status of the subjects from which
specimens have been drawn for the clinical evaluation;• details of the methods used to define the clinical status of the subjects and tocharacterize the specimens;• details of statistical methods, estimations and calculations applied;• details of the entity which performed the evaluation, including current contact details;• a declaration from the entity which performed the evaluation declaring any intereststhat could constitute a real, potential, or apparent conflict of interest with respect totheir involvement in the independent evaluation of this product or the manufacturer ofthe product.
••••

If the study has been published in peer-reviewed scientific literature, provide publication
details for the study.
NOTE: Testimonials from hospitals, laboratory staff, product users, patients, or testimonials
of any other kind are not considered to be evidence of performance. Testimonials should not
be included in the dossier as they will not be considered during review.

PQDx_018 v1 06.05.2010
Page 19 of 31

8. Labelling
The product dossier should typically contain a complete set of labelling associated with the
product. Information on labelling should include the following:•packaging labels•
instructions for use•
if applicable, the instrument manual•
any other instructional materials provided to the user.
8.1. Labels
Include copies of all the packaging labels for the assay - include outer package labels andalso component labels. These labels should include at a minimum of information:• the product name and product identification number;• the name and contact details of the manufacturer, or an authorized representative of
the manufacturer on the outer package labels;• the name of the reagent/ingredient;• the expiry date;• an indication of any special storage and/or handling conditions that apply;• the warnings and precautions;• the lot/batch and/or serial number;• the information regarding particular product conditions such as product sterility;• the names of all included reagents in each box on the outer package label.
If the product requires associated instrumentation, the above requirements also apply to the
instrument. In addition, the instrument should clearly display information regarding its
status as a new or reprocessed product.
8.2. Instructions for use
A copy of the current instructions for use should be included. If at the application form stage
the manufacturer has been required to address any issues related to the instructions for use,
the amended instructions for use should be submitted as part of the dossier. The
instructions for use will be reviewed for clarity, correctness, and suitability for the target
user group. The instructions for use should at a minimum include the following
information12:
1. The product name and product identification number.
2. The name and contact details of the manufacturer or an authorized representative of the
manufacturer, in order for the user to obtain assistance.
3. The intended use, including:a) what is detected by the assay (that is, the analytical use of the assay e.g. the marker
or nucleic acid sequence being detected);b) the clinical indication for the test (e.g. if it is for a specific disorder, or a condition orrisk factor of interest that the test is intended to detect, define or differentiate);c) the function of the product (screening, monitoring, diagnostic or aid to diagnosis,

12

Labeling requirements that apply to the WHO prequalification of diagnostics programme are based on the
document GHTF/SG1/N43:2005 Labeling for Medical Devices.
PQDx_018 v1 06.05.2010
Page 20 of 31

staging or aid to staging of disease);d) the intended user (laboratory professional and/or at point-of-care);e) the intended testing population (e.g. neonates, antenatal women);f) the type of specimen(s) required (e.g. serum, plasma, whole blood, sputum, urine).
g) whether the assay is automated;h) what the instrument is intended for;i) whether the test is qualitative or quantitative;j) an indication that the product is for in vitro use.
4. A general description of the principle of the assay method or instrument principles ofoperation.
5. A description of all components of the assay (e.g. reagents, assay controls and calibrators)
and a description of the reactive ingredients of relevant components (e.g. antibodies,
antigens, nucleic acid primers etc.).
6. A description of the specimen collection and transport materials provided with the
product or recommended for use.
7. For instruments of automated assays: a description of the appropriate assay
characteristics or dedicated assays.
8. For automated assays: a description of the appropriate instrumentation characteristics
or dedicated instrumentation.
9. If applicable, a description of any software to be used with the product.
10. If applicable, a description or complete list of the various configurations/variants ofproduct that will be made available.
11. If applicable, a description of the accessories, and other products that are intended to be
used in combination with the product.
12. Storage conditions, including storage conditions and stability of both the unopened andopened product, and working solutions. When applicable, these instructions shall include
such information as conditions of temperature, light, humidity, and other pertinent
factors.
13. Specimen exclusion criteria e.g. samples with visual evidence of hyperlipideamia or
haemolysis, excessive sample age, excessive number of freeze/thaw cycles.
14. If the test kit includes sterile accessories, an indication of that condition and anynecessary instructions in the event of damage to sterile packaging.
15. If the test kit includes accessories that have been specified by the manufacturer as
intended for single-use only, an indication of that state.
16. Clear instructions on how to perform the assay, including instructions on specimen
collection, handling, preparation and storage of reagents, the use of assay calibratorsand controls and the interpretation of results.
17. Recommendations for quality control procedures.
18. Clear instructions on the correct usage of any equipment or software that is required forthe performance of the assay.
19. Any warning and precautions to be considered related to the use of the assay including
but not limited to interpreting the results, the disposal of the assay and/or its accessories(e.g. lancets), to any consumables used with it (e.g. reagents) or to any potentially
infectious substances of human or animal origin.

PQDx_018 v1 06.05.2010
Page 21 of 31

20. Any residual risks13.
21. Precautions and measures to be taken in the event of performance changes or productmalfunction.
22. Limitations of the assay, including information on interfering substances that may affectthe performance of the assay.
23. Performance characteristics such as clinical sensitivity and specificity, seroconversion
sensitivity, accuracy, dynamic range, lower limit of detection, reproducibility, and anyother performance aspects that are relevant to the product.
24. Any requirements for special training or particular qualifications of the assay user.
25. Any requirements for routine maintenance. Include details of frequency of maintenanceand who should perform this maintenance (for example: the user, a representative of
the manufacturer, or a third party).
26. Document control details, such as a document version number and release date.
If the product requires associated instrumentation, also include a copy of the instrument
manual. If the instrument manual is large, an electronic version (CD or DVD) may be included
instead of a hard-copy.
Provide copies of any other instructional materials that are provided to the user.

9. Commercial History
9.1. Countries of supply
The information provided in this section should include:• A list all countries in which the product under assessment is currently supplied and theyear when supply started. This includes all countries where the diagnostic has been
made available, in return for payment or free-of-charge, for distribution and/or use inthat country.
• Detailed information about the training and support network that is available in eachcountry of supply. For example:a) how the users are trained in the operation of the assay;b) how the users of the product contact the supplier/manufacturer for technicalsupport;c) if there are representatives located in each country of supply to provide technicalsupport; andd) how many representatives are available in each country of supply to provide
technical support.
• The minimum and maximum price of supply for this product for the last financial year.
These prices should be the global minimum and maximum prices and should be quoted
in US dollars.
9.2. Adverse events and field safety corrective actions
This section should provide the following information:

13

For more information see ISO 14971:2007 Medical devices - Application of risk management to medical
devices.
PQDx_018 v1 06.05.2010
Page 22 of 31•A list of all adverse events that have occurred (within the last five years) that did affect,
or could have potentially affected, the performance of the assay, safety of the person
being tested, safety of users of this test, or safety of any person associated with thisproduct. Include details of the corrective and preventative action taken.

•

A list of all events (within the last five years) that required field safety corrective action
such as:a) withdrawal of products from sale or distributionb) physical return of the product to the manufacturerc) product exchanged) destruction of the producte) product modification/sf) additional advice provision to customers to ensure that the product continues tofunction as intended.

10. Regulatory History
A "National Regulatory Authority" (sometimes also called a Competent Authority) is anentity that exercises the legal right to act on behalf of the Government of a country/region
to control the use and supply of diagnostics in that country/region.
"Regulatory approval" means that the National Regulatory Authority officially permits supplyof this diagnostic in the country/region under its authority.
"Type of regulatory approval" refers to the relevant sections of legislation that have been
applied to the product for regulatory approval. Generally the details of the legislation
applied for regulatory approval should be included on the certificate that demonstrates thatthe product is approved for supply.
For the diagnostic under assessment include:• A list of National Regulatory Authorities which have provided current regulatory approval
for the supply of this product in their country/region of authority.
• Details of the type of regulatory approval obtained from each National Regulatory
Authority (this refers to the relevant sections of the legislation that have been applied tothe product for regulatory approval).
• Current evidence of this regulatory approval, such as certificates provided by the
National Regulatory Authority. The evidence should clearly show that the product underassessment falls within the scope of the submitted regulatory approval.
• Details regarding any situations where this product was rejected by a National
Regulatory Authority, situations where an application for regulatory approval waswithdrawn, or situations where regulatory approval has been withdrawn.
NOTE: Information relating to export-only regulatory approvals should be clearly identifiable
as export-only approvals.
PQDx_018 v1 06.05.2010
Page 23 of 31

11. Quality Management System
An effective quality management system is a key consideration for all manufacturers ofdiagnostics. Therefore, diagnostics submitted for prequalification assessment should bemanufactured under an appropriate quality management system. The manufacturer’squality management system should cover all sites used to manufacture this product.
The quality management standard ISO 13485:2003 Medical devices — Quality management
systems — Requirements for regulatory purposes is considered to be a benchmark in quality
management for manufacturers of diagnostics by regulatory authorities throughout theworld. WHO bases their prequalification of diagnostics assessment and inspection processeson the requirements of this internationally recognized quality management standard.
11.1. Quality manual
Include a copy of the current version of the manufacturer’s quality manual14. The following
aspects should be covered (or referred to) in the quality manual15:•
the title and scope•
the table of contents•
the review, approval and revision•
the quality policy and objectives•
the organization, responsibility and authority•
the references•
The quality management system description and•
The appendices.
Include the organizational chart of the manufacturer (if not already available within thequality manual) and document control information for the quality manual (such as version
number, release date and approval record).
A complete list of all quality management system documents, with the document title anddocument number, relevant to this product should be included.
11.2. Quality management system documents
It is expected that, to maintain an effective quality management system for the manufactureof this diagnostic, the manufacturer will utilize a number of documented procedures.
Provide copies of the following documented procedures applied in the manufacture of thisdiagnostic:• The manufacturer's documented procedure/s, relevant to this product, for the control ofdesign and development changes.

14

The manufacturer's quality manual is expected not to exceed 30 pages. However, if it does, please provide
only the electronic copy (CD or DVD) of the document.
15

These requirements are based on the ISO/TR 10013:2001 Guidelines for quality management system
documentation. For further information see the following website: www.iso.org

PQDx_018 v1 06.05.2010
Page 24 of 31

••

The manufacturer’s documented procedure/s, relevant to this product, for the provisionof advisory notices to customers subsequent to product delivery.
The manufacturer’s documented procedure/s for corrective and preventative actions for
non-conformities relating to the product under assessment.

11.3. Quality management system certification
If the manufacturer holds ISO 13485:2003 Medical devices — Quality management systems— Requirements for regulatory purposes certification for the manufacture of the productunder assessment, then provide evidence, such as certified copies of the certificates issued
by the Conformity Assessment Body. Ensure that any certificates provided clearly
demonstrate that the manufacture of the product under assessment is within the scope ofthe certification.

12. Contact Information
Any inquiries regarding the prequalification of diagnostics should be addressed to:
diagnostics@who.int

13. Reference Documents•

ISO 13485:2003 Medical devices - Quality management systems - Requirements forregulatory purposes [International Organization for Standardization (ISO) document;
www.iso.org]•

ISO/TR 10013:2001 Guidelines for quality management system documentation[International Organization for Standardization (ISO) document; www.iso.org]•

ISO 18113 Clinical laboratory testing and in vitro diagnostic test systems - In vitro
diagnostic medical devices - Information supplied by the manufacturer (labeling) - Part 1-5•

ISO/TR 18112:2006 In vitro diagnostic medical devices for professional use - Summary of
regulatory requirements for information supplied by the manufacturer•

ISO15198:2004 Clinical laboratory medicine - In vitro diagnostic medical devices Validation of user quality control procedures by the manufacturer•

ISO 17511:2003 Metrological traceability of values assigned to calibrators and control
materials•

ISO 14971:2007 Medical devices - Application of risk management to medical devices•

EN 13641:2002 Elimination or reduction of risk of infection related to in-vitro diagnostic
reagents

PQDx_018 v1 06.05.2010
Page 25 of 31

•EN 13612:2002 Performance evaluation of in vitro diagnostic medical devices•

EN 13640:2002-06 Stability testing of in vitro diagnostic reagents [European Committee
for Standardization (CEN) document www.cen.eu]•

GHTF/SG1/N41R9:2005 Essential Principles of Safety and Performance of Medical Devices[Global Harmonization Task Force (GHTF) document; www.ghtf.org]•

GHTF/SG1/N43:2005 Labelling for Medical Devices [Global Harmonization Task Force(GHTF) document; www.ghtf.org]•

GHTF/SG2/N54R8:2006 Medical Devices Post Market Surveillance: Global Guidance forAdverse Event Reporting for Medical Devices [Global Harmonization Task Force (GHTF)
document; www.ghtf.org]•

GHTF/SG2/N57R8:2006 Medical Devices Post Market Surveillance: Content of Field Safety
Notices [Global Harmonization Task Force (GHTF) document; www.ghtf.org]•

CLSI EP25-A Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline(2009)

PQDx_018 v1 06.05.2010
Page 26 of 31

14. Annex A - Essential Principles (EP) checklist
The EP checklist can be used by manufacturers to readily understand how the manufacturer
demonstrates compliance to the Essential Principles for a particular diagnostic. The EP
checklist also allows easy identification of relevant documents and data for conformity
assessment purposes.
The contents of the checklist vary among diagnostics. More complex diagnostics are more
likely to reference a larger number of standards, test reports and documents. The EP
checklist in those cases might be many pages long.
The following is a recommended template for the EP checklist. Preparation of the EP
checklist as outlined below will provide a useful overview of the manufacturer’s conformity
to the Essential Principles.
14.1. How to fill in the checklist
14.1.1. Identity of the diagnostic
The manufacturer should identify the diagnostic, and when applicable the various
configurations/variants covered by the checklist.
14.1.2. Applicable to device?
Is the listed Essential Principle applicable to the diagnostic? Here the answer is either ‘Yes’
or ‘No’. If the answer is ‘No’ this should be briefly explained.
14.1.3. Method used to demonstrate conformity
In this column, the manufacturer should state the type(s) of method(s) that it has chosen to
demonstrate conformity e.g. the recognised standard(s), industry or in-house test
method(s), comparison study(ies) or other method used.
14.1.4. Method reference
After having stated the method in the previous column, here the manufacturer should namethe title and reference the recognised standard(s), industry or in-house test method(s),comparison study(ies) or other method used to demonstrate conformity. For standards, thisshould include the date of the standard and where appropriate, the clause(s) that
demonstrates conformity with the relevant EP.
14.1.5. Reference to Supporting controlled documents
This column should contain the reference to the actual technical documentation that
demonstrates conformity to the Essential Principle, i.e. the certificates, test reports, study
reports or other documents that resulted from the method used to demonstrate conformity
and its location within the STED.

PQDx_018 v1 06.05.2010
Page 27 of 31

NOTE: The table that follows is for illustrative purposes only. The Essential Principles listed
in the first column should be extracted from the latest version of the GHTF’s guidance
document Essential principles of Safety and Performance of Medical Devices”. Those
incorporated into this document are extracted from GHTF/SG1/N41:2005.

PQDx_018 v1 06.05.2010
Page 28 of 31

Essential Principles Checklist
Identity of the diagnostic:

Essential Principle

General Requirements
5.1
Medical devices should be designed and manufactured in such a way that, whenused under the conditions and for the purposes intended and, where applicable, by virtue ofthe technical knowledge, experience, education or training of intended users, they will notcompromise the clinical condition or the safety of patients, or the safety and health of users
or, where applicable, other persons, provided that any risks which may be associated with
their use constitute acceptable risks when weighed against the benefits to the patient and arecompatible with a high level of protection of health and safety.
5.2
The solutions adopted by the manufacturer for the design and manufacture of thedevices should conform to safety principles, taking account of the generally acknowledged
state of the art. When risk reduction is required, the manufacturer should control the risk(s)so that the residual risk(s) associated with each hazard is judged acceptable. The
manufacturer should apply the following principles in the priority order listed:

identify known or foreseeable hazards and estimate the associated risks arising fromthe intended use and foreseeable misuse,

eliminate risks as far as reasonably practicable through inherently safe design andmanufacture,

reduce as far as is reasonably practicable the remaining risks by taking adequate
protection measures, including alarms,

inform users of any residual risks.

PQDx_018 v1 06.05.2010

Applicable tothe device?

Method Used
to
Demonstrate
Conformity

MethodReference

Reference to Supporting Controlled
Documents

Essential Principle

Applicable tothe device?

5.3
Devices should achieve the performance intended by the manufacturer and be
designed, manufactured and packaged in such a way that they are suitable for one or more of
the functions within the scope of the definition of a medical device applicable in eachjurisdiction.
5.4
The characteristics and performances referred to in Clauses 5.1, 5.2 and 5.3 should
not be adversely affected to such a degree that the health or safety of the patient or the user
and, where applicable, of other persons are compromised during the lifetime of the device, as
indicated by the manufacturer, when the device is subjected to the stresses which can occur
during normal conditions of use and has been properly maintained in accordance with the
manufacturer’s instructions.
5.5
The devices should be designed, manufactured and packed in such a way that theircharacteristics and performances during their intended use will not be adversely affectedunder transport and storage conditions (for example, fluctuations of temperature andhumidity) taking account of the instructions and information provided by the manufacturer.
5.6
The benefits must be determined to outweigh any undesirable side effects for the
performances intended.
Design and Manufacturing Requirements
5.7

Chemical, physical and biological properties

PQDx_018 v1 06.05.2010
Page 30 of 31

Method Used
to
Demonstrate
Conformity

MethodReference

Reference to Supporting Controlled
Documents

Essential Principle

Applicable tothe device?

5.7.1
The devices should be designed and manufactured in such a way as to ensure thecharacteristics and performance referred to in Clauses 5.1 to 5.6 of the 'General
Requirements'. Particular attention should be paid to:the choice of materials used, particularly as regards toxicity and, where appropriate,
flammability,the compatibility between the materials used and biological tissues, cells, body fluids,
and specimens, taking account of the intended purpose of the device,the choice of materials used should reflect, where appropriate, matters such as hardness,wear and fatigue strength.

5.7.2
The devices should be designed, manufactured and packed in such a way as tominimize the risk posed by contaminants and residues to the persons involved in thetransport, storage and use of the devices and to patients, taking account of the intended
purpose of the product. Particular attention should be paid to tissues exposed and to theduration and frequency of exposure.
5.7.3------------------------------- etc. --------------------------------------------

5.7.4------------------------------- etc. --------------------------------------------

5.7.5
5.7.6

PQDx_018 v1 06.05.2010
Page 31 of 31

Method Used
to
Demonstrate
Conformity

MethodReference

Reference to Supporting Controlled
Documents